Suraksha Diagnostic Limited (NSE:SURAKSHA)
India · Delayed Price · Currency is INR 355.95
+5.55 (1.58%)
Nov 11, 2026, 1:30 PM IST
Suraksha Diagnostic Revenue
Suraksha Diagnostic had revenue of 1.01B INR in the quarter ending September 30, 2026, with 27.75% growth. This brings the company's total for the last twelve months to 3.47B, up 25.63% year-over-year. In the fiscal year ending March 31, 2026, Suraksha Diagnostic had annual revenue of 3.10B with 23.13% growth. That makes Suraksha Diagnostic the 30,036th largest company in the world by revenue and 2,106th in India.
Revenue (ttm)
3.47B
Revenue Growth
+25.63%
P/S Ratio
5.26
Revenue / Employee
2.17M
Employees
1,600
Market Cap
18.54B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 3.10B | 583.21M | 23.13% |
| Mar 31, 2025 | 2.52B | 333.84M | 15.26% |
| Mar 31, 2024 | 2.19B | 285.75M | 15.03% |
| Mar 31, 2023 | 1.90B | -330.59M | -14.81% |
| Mar 31, 2022 | 2.23B | 831.87M | 59.42% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 616.31B |
| Divi's Laboratories | 121.91B |
| Lenskart Solutions | 103.83B |
| Laurus Labs | 78.23B |
| Indoco Remedies | 19.09B |
| Windlas Biotech | 9.93B |
| Krsnaa Diagnostics | 8.86B |
| Sai Parenteral's | 6.74B |